Longeveron Inc. is a clinical-stage biotechnology company developing cellular therapies focused on aging-related and life-threatening conditions. The company's primary investigational product is LOMECEL-B, an allogeneic mesenchymal stem cell formulation derived from bone marrow of young, healthy adult donors. LOMECEL-B is currently in phase 1 clinical trials for hypoplastic left heart syndrome, has completed phase 2a testing for Alzheimer's disease, and is in phase 2b trials for aging frailty.
The company operates as a pre-revenue clinical-stage entity with no established business segments or commercial revenue streams. Development activities are concentrated on advancing LOMECEL-B through the clinical trial pipeline and establishing proof of efficacy across its target indications.
Longeveron is headquartered in Miami, Florida, and operates with a team of 25 full-time employees. The company was incorporated in Delaware in 2014 and is publicly listed on Nasdaq.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-2.62 | $-2.62 | -156.9% | |
| 2023 | $-1.02 | $-1.02 | -13.3% | |
| 2022 | $-0.90 | $-0.90 | — | |
| 2021 | — | — | — |